Want to see IFRX full AI Analyst Report?
InflaRx (IFRX) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Cohort A: Vilobelimab, Cohort B: Paridiprubart, Cohort C: Bevacizumab | Ards, Acute Respiratory Distress Syndrome (Ards), Acute Respiratory Distress Syndrome, Ards (Acute Respiratory Distress Syndrome) | Phase II | Recruiting | JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record) | Nov 20, 2024 | ― |
| Cohort A: Vilobelimab | Ards, Acute Respiratory Distress Syndrome (Ards), Acute Respiratory Distress Syndrome, Ards (Acute Respiratory Distress Syndrome) | Phase II | Recruiting | JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab | Nov 20, 2024 | ― |
| Cohort C: Bevacizumab | Ards, Acute Respiratory Distress Syndrome (Ards), Acute Respiratory Distress Syndrome, Ards (Acute Respiratory Distress Syndrome) | Phase II | Recruiting | JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab | Nov 20, 2024 | ― |
| Cohort B: Paridiprubart | Ards, Acute Respiratory Distress Syndrome (Ards), Acute Respiratory Distress Syndrome, Ards (Acute Respiratory Distress Syndrome) | Phase II | Recruiting | JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart | Nov 20, 2024 | ― |
| Csu Lower Dose Treatment, Csu High Dose Treatment, Csu Non Responders Ige - High Dose Treatment, Hs Low Dose Treatment, Hs Medium Dose Treatment, Hs High Dose Treatment | Hidradenitis Suppurativa, Hidradenitis, Chronic Urticaria, Idiopathic | Phase II | Recruiting | Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa | Aug 07, 2024 | ― |
| Vilobelimab | Pyoderma Gangrenosum | Phase III | Terminated | Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum | Jun 29, 2023 | ― |
| Vilobelimab, Vilobelimab + Pembrolizumab Combination Therapy | Scc - Squamous Cell Carcinoma Of Skin | Phase II | Terminated | Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC. | Mar 10, 2021 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Cohort A: Vilobelimab, Cohort B: Paridiprubart, Cohort C: Bevacizumab | Phase II | Ards, Acute Respiratory Distress Syndrome (Ards), Acute Respiratory Distress Syndrome, Ards (Acute Respiratory Distress Syndrome) | Recruiting | JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record) | Nov 20, 2024 | ― |
| Cohort A: Vilobelimab | Phase II | Ards, Acute Respiratory Distress Syndrome (Ards), Acute Respiratory Distress Syndrome, Ards (Acute Respiratory Distress Syndrome) | Recruiting | JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab | Nov 20, 2024 | ― |
| Cohort C: Bevacizumab | Phase II | Ards, Acute Respiratory Distress Syndrome (Ards), Acute Respiratory Distress Syndrome, Ards (Acute Respiratory Distress Syndrome) | Recruiting | JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab | Nov 20, 2024 | ― |
| Cohort B: Paridiprubart | Phase II | Ards, Acute Respiratory Distress Syndrome (Ards), Acute Respiratory Distress Syndrome, Ards (Acute Respiratory Distress Syndrome) | Recruiting | JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart | Nov 20, 2024 | ― |
| Csu Lower Dose Treatment, Csu High Dose Treatment, Csu Non Responders Ige - High Dose Treatment, Hs Low Dose Treatment, Hs Medium Dose Treatment, Hs High Dose Treatment | Phase II | Hidradenitis Suppurativa, Hidradenitis, Chronic Urticaria, Idiopathic | Recruiting | Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa | Aug 07, 2024 | ― |
| Vilobelimab | Phase III | Pyoderma Gangrenosum | Terminated | Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum | Jun 29, 2023 | ― |
| Vilobelimab, Vilobelimab + Pembrolizumab Combination Therapy | Phase II | Scc - Squamous Cell Carcinoma Of Skin | Terminated | Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC. | Mar 10, 2021 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Inflarx N.V. (IFRX) have in its pipeline
InflaRx IFRX is currently developing the following drugs: Cohort A: Vilobelimab, Cohort B: Paridiprubart, Cohort C: Bevacizumab, Cohort A: Vilobelimab, Cohort C: Bevacizumab, Cohort B: Paridiprubart, Csu Lower Dose Treatment, Csu High Dose Treatment, Csu Non Responders Ige - High Dose Treatment, Hs Low Dose Treatment, Hs Medium Dose Treatment, Hs High Dose Treatment, Vilobelimab, Vilobelimab, Vilobelimab + Pembrolizumab Combination Therapy. These drug candidates are in various stages of clinical development as the company works toward FDA approval.